Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Milliarden-Deal: Accenture übernimmt Netzwerkanalyse-Spezialisten Ookla (Heise) +++ ZIFF DAVIS Aktie -10,50%

MODERNA Aktie

 >MODERNA Aktienkurs 
42.915 EUR    -5.1%    (TradegateBSX)
Ask: 42.94 EUR / 70 Stück
Bid: 42.85 EUR / 80 Stück
Tagesumsatz: 49934 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
MODERNA Aktie über LYNX handeln
>MODERNA Performance
1 Woche: 0%
1 Monat: +20,2%
3 Monate: +99,3%
6 Monate: +109,4%
1 Jahr: +48,3%
laufendes Jahr: +61,6%
>MODERNA Aktie
Name:  MODERNA INC. DL-,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US60770K1079 / A2N9D9
Symbol/ Ticker:  0QF (Frankfurt) / MRNA (NASDAQ)
Kürzel:  FRA:0QF, ETR:0QF, 0QF:GR, NASDAQ:MRNA
Index:  S&P500
Webseite:  https://www.modernatx.com..
Profil:  Moderna, Inc. is a biotechnology company specializing in the research, development, and provision of messenger RNA (mRNA) medicines in the United States, Europe, and internationally. Its primary funct..
>Volltext..
Marktkapitalisierung:  18000.33 Mio. EUR
Unternehmenswert:  14142.56 Mio. EUR
Umsatz:  1676.65 Mio. EUR
EBITDA:  -2465.81 Mio. EUR
Nettogewinn:  -2433.9 Mio. EUR
Gewinn je Aktie:  -6.26 EUR
Schulden:  1125.53 Mio. EUR
Liquide Mittel:  2238.98 Mio. EUR
Operativer Cashflow:  -1615.41 Mio. EUR
Bargeldquote:  2.92
Umsatzwachstum:  -47.05%
Gewinnwachstum:  30.15%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 8.540.887 USD.
Suchwörter:  MODERNA
Letzte Datenerhebung:  04.03.26
>MODERNA Kennzahlen
Aktien/ Unternehmen:
Aktien: 394.94 Mio. St.
Frei handelbar: 91.46%
Rückkaufquote: -0.17%
Mitarbeiter: 4700
Umsatz/Mitarb.: 0.36 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -19.66%
Bewertung:
KGV: -
KGV lG: -
KUV: 10.63
KBV: 2.32
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 44.29%
Gewinnmarge: -145.16%
Operative Marge: -158.13%
Managementeffizenz:
Gesamtkaprendite: -21.31%
Eigenkaprendite: -28.87%
>MODERNA Peer Group
Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, mRNA- Forschung/ Impfstoffe, Onkologie/ Krebs- Behandlung, Impfstoffentwicklung/ Impfstoffhersteller, Covid 19- Behandlung
 
04.03.26 - 05:02
Insiderhandel: Chief Legal Officer verkauft Aktien von Moderna im Wert von 726047 USD (Insiderkauf)
 
Klinger, Shannon Thyme - Vorstand - Tag der Transaktion: 2026-03-02...
04.03.26 - 03:06
CrowdStrike, Mobix Labs, Micron Technology, Target And Moderna: Why These 5 Stocks Are On Investors′ Radars Today (Benzinga)
 
U.S. stocks finished Tuesday lower as mounting tensions in the conflict with Iran weighed on sentiment. The Dow Jones Industrial Average slid 0.8% to 48,501.27. Importance Rank:  1 read more...
04.03.26 - 00:36
Moderna Stock Jumps 10% After Hours: Here′s Why (Benzinga)
 
Moderna shares are rising in Tuesday's after-hours session after the company announced it reached a settlement agreement. Importance Rank:  1 read more...
03.03.26 - 23:36
Moderna’s stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline (MarketWatch)
 
The deal would provide 'certainty' for Moderna's vaccine portfolio....
03.03.26 - 23:21
Moderna surges after hours on patent settlement with Arbutus and Genevant (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.03.26 - 23:18
Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus (AFX)
 
WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary......
03.03.26 - 22:54
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant (WSJ EN)
 
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor....
03.03.26 - 22:48
Moderna to Pay Almost $1 Billion to Settle Arbutus Litigation (Bloomberg)
 
Moderna Inc. agreed to pay $950 million to settle all litigation worldwide with Arbutus Biopharma Corp. and Genevant Sciences GmbH over the company's existing and future vaccines, with no future royalties owed....
03.03.26 - 22:42
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute (Reuters EN)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
03.03.26 - 22:31
Moderna, Inc.: Moderna Resolves Global Patent Litigation with Arbutus/Genevant (Accesswire)
 
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026District Court's Section 1498 decision to be appealed to the Federal C......
03.03.26 - 22:17
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna (GlobeNewswire EN)
 
BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna's unauthorized use of Genevant's and Arbutus' LNP delivery technology in its COVID-19 vaccines, including Spikevax®....
03.03.26 - 22:17
Roivant Announces Genevant Sciences′ and Arbutus Biopharma′s $2.25 Billion Global Settlement With Moderna (GlobeNewswire EN)
 
BASEL, Switzerland and LONDON and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant, and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna's unauthorized use of Genevant's and Arbutus' LNP delivery technology in its COVID-19 vaccines, including Spikevax®....
02.03.26 - 15:01
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot (Zacks)
 
Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines....
27.02.26 - 21:45
European health agency recommends approving Moderna′s combined flu, COVID vaccine (The Hill)
 
The European Medicines Agency (EMA) announced Friday it has recommended Moderna's combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the first time the combined respiratory viral vaccine will be approved. "EMA has recommended granting a marketing authorisation in the European Union (EU) for mCombriax, a messenger RNA vaccine......
27.02.26 - 18:12
Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung (Der Aktionaer)
 
Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen werden, teilte die Behörde in Amsterdam mit....
27.02.26 - 15:33
EMA recommends authorization of Moderna combination COVID/flu vaccine (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.02.26 - 15:15
Impfstoff: Moderna erhält EU–Zulassung für Impfstoff gegen Covid und Grippe (Handelsblatt)
 
Die Europäische Arzneimittelagentur empfiehlt den ersten Kombinationsimpfstoff gegen Grippe und Covid von Moderna – ein wichtiger Erfolg für den Konzern....
27.02.26 - 13:06
Moderna, Inc.: European Medicines Agency′s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna′s mRNA Combination Vaccine Against Influenza and COVID-19 (Accesswire)
 
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positi......
27.02.26 - 12:12
Moderna Gets EU Approval for mRNA Combination Covid-Flu Shot (Bloomberg)
 
European regulators have approved Moderna Inc.'s novel combination flu and Covid shot, handing a victory to the embattled vaccine maker that's faced heavy resistance to its new immunizations in the US....
26.02.26 - 02:01
Insiderhandel: President verkauft Aktien von Moderna im Wert von 7814840 USD (Insiderkauf)
 
Hoge, Stephen - Vorstand - Tag der Transaktion: 2026-02-23...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer ein blindes Pferd verkaufen will, lobt die Füße. - Bauernregel - Bauernweisheit
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!